We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
Read MoreHide Full Article
HCA Healthcare, Inc. (HCA - Free Report) recently unveiled the Enhanced Surgical Recovery (ESR) program, a patient-focused, research-backed and multidisciplinary approach to bring about faster recovery of patients post surgery.
Shares of HCA Healthcare gained 0.7% on Dec 14.
Originating from a recovery program (Enhanced Recovery After Surgery [ERAS]) that has been in use across Europe for a long time, the ESR program of HCA Healthcare has been embraced by 167 of its healthcare facilities.
The program works by leveraging pre-, intra- and post-operative intervention that equips HCA Healthcare to devise a better experience for patients and enables them to quickly return to their daily life.
The patients participating in the ESR program can benefit from a reduction in the length of stay at hospitals, lesser need for readmissions and reduced opioid usage. Reduced readmissions will save healthcare costs for individuals. Also, frequent readmissions tend to put pressure on a nation's healthcare system.
Apart from being of great use to patients, an effective ESR program might lure more patients to choose HCA Healthcare while undergoing surgeries. This, in turn, is expected to boost revenues from performing surgeries. The healthcare provider remains steadfast in developing enhanced practices aimed at providing better care through leveraging data from roughly 35 million patients in a year.
HCA Healthcare has undertaken a wide array of measures to build a solid healthcare suite. For complementing the same, it has often resorted to buyouts and collaborations that have enhanced its capabilities, boosted patient volumes and diversified the treatment network. To establish its presence across the growing cancer therapeutics market, HCA entered into a joint venture with McKesson (MCK - Free Report) this June in order to strengthen the cancer offerings suite of both partners
Shares of HCA Healthcare have gained 42.7% in the past six months compared with the industry’s 32.3% rally.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
HCA Healthcare currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) and ShockWave Medical, Inc. (SWAV - Free Report) . While Medpace sports a Zacks Rank #1 (Strong Buy), ShockWave Medical carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace’s earnings surpassed estimates in each of the last four quarters, the average surprise being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9% from the year-ago reported figure, while the same for revenues indicates growth of 27.1%. The consensus mark for MEDP’s 2022 earnings has moved north by 13.1% in the past 60 days.
The bottom line of ShockWave Medical outpaced estimates in each of the trailing four quarters, the average surprise being 146.10%. The Zacks Consensus Estimate for SWAV’s 2022 earnings is pegged at $2.92 per share. A loss of 26 cents per share was reported in the prior year. The consensus mark for SWAV’s 2022 earnings has moved north by 1.4% in the past 30 days.
Shares of Medpace and ShockWave Medical have surged 59.2% and 40.7%, respectively, in the past six months.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
HCA Healthcare, Inc. (HCA - Free Report) recently unveiled the Enhanced Surgical Recovery (ESR) program, a patient-focused, research-backed and multidisciplinary approach to bring about faster recovery of patients post surgery.
Shares of HCA Healthcare gained 0.7% on Dec 14.
Originating from a recovery program (Enhanced Recovery After Surgery [ERAS]) that has been in use across Europe for a long time, the ESR program of HCA Healthcare has been embraced by 167 of its healthcare facilities.
The program works by leveraging pre-, intra- and post-operative intervention that equips HCA Healthcare to devise a better experience for patients and enables them to quickly return to their daily life.
The patients participating in the ESR program can benefit from a reduction in the length of stay at hospitals, lesser need for readmissions and reduced opioid usage. Reduced readmissions will save healthcare costs for individuals. Also, frequent readmissions tend to put pressure on a nation's healthcare system.
Apart from being of great use to patients, an effective ESR program might lure more patients to choose HCA Healthcare while undergoing surgeries. This, in turn, is expected to boost revenues from performing surgeries. The healthcare provider remains steadfast in developing enhanced practices aimed at providing better care through leveraging data from roughly 35 million patients in a year.
HCA Healthcare has undertaken a wide array of measures to build a solid healthcare suite. For complementing the same, it has often resorted to buyouts and collaborations that have enhanced its capabilities, boosted patient volumes and diversified the treatment network. To establish its presence across the growing cancer therapeutics market, HCA entered into a joint venture with McKesson (MCK - Free Report) this June in order to strengthen the cancer offerings suite of both partners
Shares of HCA Healthcare have gained 42.7% in the past six months compared with the industry’s 32.3% rally.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
HCA Healthcare currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Medical space are Medpace Holdings, Inc. (MEDP - Free Report) and ShockWave Medical, Inc. (SWAV - Free Report) . While Medpace sports a Zacks Rank #1 (Strong Buy), ShockWave Medical carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace’s earnings surpassed estimates in each of the last four quarters, the average surprise being 22.04%. The Zacks Consensus Estimate for MEDP’s 2022 earnings suggests an improvement of 44.9% from the year-ago reported figure, while the same for revenues indicates growth of 27.1%. The consensus mark for MEDP’s 2022 earnings has moved north by 13.1% in the past 60 days.
The bottom line of ShockWave Medical outpaced estimates in each of the trailing four quarters, the average surprise being 146.10%. The Zacks Consensus Estimate for SWAV’s 2022 earnings is pegged at $2.92 per share. A loss of 26 cents per share was reported in the prior year. The consensus mark for SWAV’s 2022 earnings has moved north by 1.4% in the past 30 days.
Shares of Medpace and ShockWave Medical have surged 59.2% and 40.7%, respectively, in the past six months.